+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Osteoporosis Drugs Market, By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), and Others), By Osteoporosis Disease Type, By Route of Administration, By Gender, By Distribution Channel, By Region, Forecast & Opportunities, 2026

  • ID: 5306204
  • Report
  • March 2021
  • Region: Global
  • 112 pages
  • TechSci Research

FEATURED COMPANIES

  • Abiogen Pharma S.p.A
  • Allergan plc
  • Amgen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Global Osteoporosis Drugs Market stood at USD13.36 billion in 2020 and is projected to grow at a CAGR of 6.83% to cross USD20.17 billion by 2026. The increase in the prevalence of osteoporosis in postmenopausal women and rising awareness among the public about osteoporosis care are some key factors propelling the market growth. Moreover, growing investment in R&D activities for the development of advanced new drug classes and a wide range of pipeline drugs for approval in clinical trials are expected to provide lucrative growth opportunities for osteoporosis drug manufacturers.

Osteoporosis drugs are used to treat osteoporosis, which is a bone disease. Osteoporosis may occur due to lower than normal peak bone mass and greater than normal bone mass loss. Other reasons behind this disease include a number of diseases or treatments such as anorexia, surgical removal of the ovaries, hyperthyroidism, alcoholism, and kidney disease. Moreover, lifestyle associated factors such as smoking and alcohol abuse can also promote osteoporosis. Hence these factors are leading to a spike in the demand for osteoporosis drugs around the world.

The Global Osteoporosis Drugs Market can be segmented based on disease type, drug class, route of administration, gender, distribution channel and region. Based on the route of administration, the market can be segmented into oral, injectable, and others. Among them, the injectable segment is expected to witness high CAGR during the forecast period owing to the growing need for drugs that exhibit improved bioavailability rapid mode of action.

Regionally, North America dominated the Global Osteoporosis Drugs Market in 2020 owing to the rising prevalence of osteoporosis and easy availability of osteoporosis drugs in the region. However, Asia Pacific is expected to witness the fastest growth through 2026 owing to growing awareness about the benefits of osteoporosis drugs and thriving life science industry.

Major companies operating in the Global Osteoporosis Drugs Market include F. Hoffmann-La Roche Ltd, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Novartis International AG, GlaxoSmithKline Plc, Merck & Co. Inc., Amgen, Inc., Allergan plc, Eli Lilly and Company, Radius Health, Inc., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited, Sanofi S.A., Abiogen Pharma S.p.A., Merrion Pharmaceuticals Plc., among others. The market players are taking up growth strategies like collaborations, new product launches, partnership & acquisitions.

Years considered for this report:
  • Historical Years: 2016-2019
  • Base Year: 2020
  • Estimated Year: 2021
  • Forecast Period: 2022-2026
Objective of the Study:
  • To analyze the historical growth in the market size of the Global Osteoporosis Drugs Market from 2016 to 2019.
  • To estimate and forecast the market size of the Global Osteoporosis Drugs Market from 2021 to 2026 and growth rate until 2026.
  • To forecast the Global Osteoporosis Drugs Market based on drug class, route of administration, company and regional distribution.
  • To identify drivers and challenges for the Global Osteoporosis Drugs Market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in the Global Osteoporosis Drugs Market.
  • To identify and analyze the profile of leading players operating in the Global Osteoporosis Drugs Market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of osteoporosis drug manufacturers across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the companies which could not be identified due to the limitations of secondary research.

The publisher calculated the Global Osteoporosis Drugs Market size by using a bottom-up approach, where data for various end-user industries and its application across various product types were recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used.

Key Target Audience:
  • Osteoporosis drugs manufacturers, companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to osteoporosis drugs
  • Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as osteoporosis drug manufacturing companies, end-users etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.

Report Scope:

In this report, the Global Osteoporosis Drugs Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Osteoporosis Drugs Market, By Osteoporosis Disease Type:
  • Primary Osteoporosis
  • Secondary Osteoporosis
Global Osteoporosis Drugs Market, By Drug Class:
  • Bisphosphonates
  • Selective Estrogen Inhibitors Modulator (SERM)
  • Parathyroid Hormone Therapy
  • Calcitonin
  • Rank Ligand Inhibitors
  • Others
Global Osteoporosis Drugs Market, By Route of Administration:
  • Oral
  • Injectable
  • Others
Global Osteoporosis Drugs Market, By Gender:
  • Male
  • Female
Global Osteoporosis Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Global Osteoporosis Drugs Market, By Region:
  • North America
  • United States
  • Mexico
  • Canada
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
Competitive Landscape
  • Company Profiles: Detailed analysis of the major companies present in the Global Osteoporosis Drugs Market.
Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abiogen Pharma S.p.A
  • Allergan plc
  • Amgen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Osteoporosis Drugs Market

4. Executive Summary

5. Voice of Customer

6. Global Osteoporosis Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others)
6.2.2. By Route of Administration (Oral, Injectable, and Others)
6.2.3. By Osteoporosis Disease Type (Primary Osteoporosis, Secondary Osteoporosis)
6.2.4. By Gender (Female, Male)
6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.6. By Company (2020)
6.2.7. By Region
6.3. Product Market Map

7. North America Osteoporosis Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Route of Administration
7.2.3. By Osteoporosis Disease Type
7.2.4. By Gender
7.2.5. By Distribution Channel
7.2.6. By Country
7.3. North America: Country Analysis
7.3.1. United States Osteoporosis Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Osteoporosis Disease Type
7.3.1.2.4. By Gender
7.3.1.2.5. By Distribution Channel
7.3.2. Mexico Osteoporosis Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Osteoporosis Disease Type
7.3.2.2.4. By Gender
7.3.2.2.5. By Distribution Channel
7.3.3. Canada Osteoporosis Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Osteoporosis Disease Type
7.3.3.2.4. By Gender
7.3.3.2.5. By Distribution Channel

8. Europe Osteoporosis Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of Administration
8.2.3. By Osteoporosis Disease Type
8.2.4. By Gender
8.2.5. By Distribution Channel
8.2.6. By Country
8.3. Europe: Country Analysis
8.3.1. France Osteoporosis Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Osteoporosis Disease Type
8.3.1.2.4. By Gender
8.3.1.2.5. By Distribution Channel
8.3.2. Germany Osteoporosis Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Osteoporosis Disease Type
8.3.2.2.4. By Gender
8.3.2.2.5. By Distribution Channel
8.3.3. United Kingdom Osteoporosis Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Osteoporosis Disease Type
8.3.3.2.4. By Gender
8.3.3.2.5. By Distribution Channel
8.3.4. Italy Osteoporosis Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Osteoporosis Disease Type
8.3.4.2.4. By Gender
8.3.4.2.5. By Distribution Channel
8.3.5. Spain Osteoporosis Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Osteoporosis Disease Type
8.3.5.2.4. By Gender
8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Osteoporosis Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Route of Administration
9.2.3. By Osteoporosis Disease Type
9.2.4. By Gender
9.2.5. By Distribution Channel
9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Osteoporosis Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Osteoporosis Disease Type
9.3.1.2.4. By Gender
9.3.1.2.5. By Distribution Channel
9.3.2. India Osteoporosis Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Osteoporosis Disease Type
9.3.2.2.4. By Gender
9.3.2.2.5. By Distribution Channel
9.3.3. Japan Osteoporosis Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Osteoporosis Disease Type
9.3.3.2.4. By Gender
9.3.3.2.5. By Distribution Channel
9.3.4. South Korea Osteoporosis Drugs Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Class
9.3.4.2.2. By Route of Administration
9.3.4.2.3. By Osteoporosis Disease Type
9.3.4.2.4. By Gender
9.3.4.2.5. By Distribution Channel
9.3.5. Singapore Osteoporosis Drugs Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Drug Class
9.3.5.2.2. By Route of Administration
9.3.5.2.3. By Osteoporosis Disease Type
9.3.5.2.4. By Gender
9.3.5.2.5. By Distribution Channel
9.3.6. Australia Osteoporosis Drugs Market Outlook
9.3.6.1. Market Size & Forecast
9.3.6.1.1. By Value
9.3.6.2. Market Share & Forecast
9.3.6.2.1. By Drug Class
9.3.6.2.2. By Route of Administration
9.3.6.2.3. By Osteoporosis Disease Type
9.3.6.2.4. By Gender
9.3.6.2.5. By Distribution Channel

10. South America Osteoporosis Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Route of Administration
10.2.3. By Osteoporosis Disease Type
10.2.4. By Gender
10.2.5. By Distribution Channel
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Osteoporosis Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Osteoporosis Disease Type
10.3.1.2.4. By Gender
10.3.1.2.5. By Distribution Channel
10.3.2. Argentina Osteoporosis Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Osteoporosis Disease Type
10.3.2.2.4. By Gender
10.3.2.2.5. By Distribution Channel
10.3.3. Colombia Osteoporosis Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Osteoporosis Disease Type
10.3.3.2.4. By Gender
10.3.3.2.5. By Distribution Channel

11. Middle East and Africa Osteoporosis Drugs Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Class
11.2.2. By Route of Administration
11.2.3. By Osteoporosis Disease Type
11.2.4. By Gender
11.2.5. By Distribution Channel
11.2.6. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Osteoporosis Drugs Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Class
11.3.1.2.2. By Route of Administration
11.3.1.2.3. By Osteoporosis Disease Type
11.3.1.2.4. By Gender
11.3.1.2.5. By Distribution Channel
11.3.2. Saudi Arabia Osteoporosis Drugs Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Class
11.3.2.2.2. By Route of Administration
11.3.2.2.3. By Osteoporosis Disease Type
11.3.2.2.4. By Gender
11.3.2.2.5. By Distribution Channel
11.3.3. UAE Osteoporosis Drugs Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Class
11.3.3.2.2. By Route of Administration
11.3.3.2.3. By Osteoporosis Disease Type
11.3.3.2.4. By Gender
11.3.3.2.5. By Distribution Channel

12. Market Dynamics
12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape
14.1. Competition Outlook
14.2. Players Profiled (Leading Companies)
14.2.1. F. Hoffmann-La Roche Ltd
14.2.2. Pfizer, Inc.
14.2.3. Teva Pharmaceuticals Industries Ltd.
14.2.4. Novartis International AG
14.2.5. GlaxoSmithKline Plc
14.2.6. Merck & Co. Inc.
14.2.7. Amgen, Inc.
14.2.8. Allergan plc
14.2.9. Eli Lilly and Company
14.2.10. Radius Health, Inc.
14.2.11. Sun Pharmaceutical Industries Ltd.
14.2.12. Takeda Pharmaceutical Company Limited
14.2.13. Sanofi S.A.
14.2.14. Abiogen Pharma S.p.A
14.2.15. Merrion Pharmaceuticals Plc

15. Strategic Recommendations

16. About the Publisher & Disclaimer
(Note: The companies list can be customized based on the client requirements.)

List of Figures
Figure 1: Global Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 2: Global Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 3: Global Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 4: Global Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 5: Global Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 6: Global Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 7: Global Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 8: North America Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 9: North America Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 10: North America Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 11: North America Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 12: North America Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 13: North America Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 14: North America Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 15: United States Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 16: United States Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 17: United States Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 18: United States Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 19: United States Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 20: United States Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 21: United States Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 22: Mexico Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 23: Mexico Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 24: Mexico Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 25: Mexico Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 26: Mexico Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 27: Mexico Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 28: Mexico Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 29: Canada Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 30: Canada Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 31: Canada Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 32: Canada Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 33: Canada Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 34: Canada Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 35: Canada Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 36: Europe Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 37: Europe Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 38: Europe Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 39: Europe Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 40: Europe Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 41: Europe Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 42: Europe Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 43: France Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 44: France Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 45: France Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 46: France Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 47: France Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 48: France Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 49: France Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 50: Germany Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 51: Germany Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 52: Germany Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 53: Germany Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 54: Germany Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 55: Germany Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 56: Germany Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 57: United Kingdom Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 58: United Kingdom Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 59: United Kingdom Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 60: United Kingdom Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 61: United Kingdom Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 62: United Kingdom Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 63: United Kingdom Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 64: Italy Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 65: Italy Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 66: Italy Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 67: Italy Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 68: Italy Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 69: Italy Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 70: Italy Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 71: Spain Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 72: Spain Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 73: Spain Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 74: Spain Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 75: Spain Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 76: Spain Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 77: Spain Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 78: Asia-Pacific Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 79: Asia-Pacific Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 80: Asia-Pacific Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 81: Asia-Pacific Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 82: Asia-Pacific Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 83: Asia-Pacific Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 84: Asia-Pacific Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 85: China Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 86: China Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 87: China Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 88: China Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 89: China Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 90: China Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 91: China Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 92: India Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 93: India Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 94: India Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 95: India Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 96: India Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 97: India Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 98: India Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 99: Japan Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 100: Japan Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 101: Japan Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 102: Japan Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 103: Japan Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 104: Japan Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 105: Japan Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 106: South Korea Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 107: South Korea Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 108: South Korea Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 109: South Korea Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 110: South Korea Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 111: South Korea Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 112: South Korea Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 113: Singapore Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 114: Singapore Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 115: Singapore Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 116: Singapore Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 117: Singapore Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 118: Singapore Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 119: Singapore Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 120: Australia Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 121: Australia Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 122: Australia Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 123: Australia Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 124: Australia Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 125: Australia Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 126: Australia Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 127: South America Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 128: South America Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 129: South America Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 130: South America Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 131: South America Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 132: South America Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 133: South America Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 134: Brazil Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 135: Brazil Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 136: Brazil Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 137: Brazil Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 138: Brazil Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 139: Brazil Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 140: Brazil Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 141: Argentina Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 142: Argentina Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 143: Argentina Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 144: Argentina Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 145: Argentina Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 146: Argentina Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 147: Argentina Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 148: Colombia Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 149: Colombia Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 150: Colombia Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 151: Colombia Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 152: Colombia Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 153: Colombia Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 154: Colombia Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 155: Middle East and Africa Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 156: Middle East and Africa Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 157: Middle East and Africa Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 158: Middle East and Africa Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 159: Middle East and Africa Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 160: Middle East and Africa Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 161: Middle East and Africa Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 162: South Africa Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 163: South Africa Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 164: South Africa Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 165: South Africa Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 166: South Africa Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 167: South Africa Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 168: South Africa Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 169: South Arabia Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 170: South Arabia Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 171: South Arabia Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 172: South Arabia Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 173: South Arabia Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 174: South Arabia Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 175: South Arabia Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Figure 176: UAE Osteoporosis Drugs Market Size, By Value (USD Billion), 2016-2026F
Figure 177: UAE Osteoporosis Drugs Market Share, By Drug Class, 2016-2026F
Figure 178: UAE Osteoporosis Drugs Market Share, By Route of Administration, 2016-2026F
Figure 179: UAE Osteoporosis Drugs Market Share, By Osteoporosis Disease Type, 2016-2026F
Figure 180: UAE Osteoporosis Drugs Market Share, By Gender, 2016-2026F
Figure 181: UAE Osteoporosis Drugs Market Share, By Distribution Channel, 2016-2026F
Figure 182: UAE Osteoporosis Drugs Market, Market Map, By Region, By Value, 2016-2026F
Note: Product cover images may vary from those shown
  • F. Hoffmann-La Roche Ltd
  • Pfizer, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis International AG
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Amgen, Inc.
  • Allergan plc
  • Eli Lilly and Company
  • Radius Health, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Abiogen Pharma S.p.A
  • Merrion Pharmaceuticals Plc
Note: Product cover images may vary from those shown
Adroll
adroll